Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population.

Bosch LJW, Melotte V, Mongera S, Daenen KLJ, Coupé VMH, van Turenhout ST, Stoop EM, de Wijkerslooth TR, Mulder CJJ, Rausch C, Kuipers EJ, Dekker E, Domanico MJ, Lidgard GP, Berger BM, van Engeland M, Carvalho B, Meijer GA.

Am J Gastroenterol. 2019 Dec;114(12):1909-1918. doi: 10.14309/ajg.0000000000000445.

2.

Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma.

Qin Y, Wu CW, Taylor WR, Sawas T, Burger KN, Mahoney DW, Sun Z, Yab TC, Lidgard GP, Allawi HT, Buttar NS, Smyrk TC, Iyer PG, Katzka DA, Ahlquist DA, Kisiel JB.

Clin Cancer Res. 2019 Dec 15;25(24):7396-7404. doi: 10.1158/1078-0432.CCR-19-0740. Epub 2019 Sep 16.

PMID:
31527170
3.

Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls.

Majumder S, Raimondo M, Taylor WR, Yab TC, Berger CK, Dukek BA, Cao X, Foote PH, Wu CW, Devens ME, Mahoney DW, Smyrk TC, Pannala R, Chari ST, Vege SS, Topazian MD, Petersen BT, Levy MJ, Rajan E, Gleeson FC, Abu Dayyeh B, Nguyen CC, Faigel DO, Woodward TA, Wallace MB, Petersen G, Allawi HT, Lidgard GP, Kisiel JB, Ahlquist DA.

Clin Gastroenterol Hepatol. 2020 Mar;18(3):676-683.e3. doi: 10.1016/j.cgh.2019.07.017. Epub 2019 Jul 16.

PMID:
31323382
4.

Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing.

Majumder S, Taylor WR, Yab TC, Berger CK, Dukek BA, Cao X, Foote PH, Wu CW, Mahoney DW, Aslanian HR, Fernández-Del Castillo C, Doyle LA, Farrell JJ, Fisher WE, Lee LS, Lee YN, Park W, Rodrigues C, Gould Rothberg BE, Salem RR, Simeone DM, Urs S, Van Buren G, Smyrk TC, Allawi HT, Lidgard GP, Raimondo M, Chari ST, Kendrick ML, Kisiel JB, Topazian MD, Ahlquist DA.

Am J Gastroenterol. 2019 Sep;114(9):1539-1549. doi: 10.14309/ajg.0000000000000284.

PMID:
31306149
5.

Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation.

Kisiel JB, Dukek BA, V S R Kanipakam R, Ghoz HM, Yab TC, Berger CK, Taylor WR, Foote PH, Giama NH, Onyirioha K, Abdallah MA, Burger KN, Slettedahl SW, Mahoney DW, Smyrk TC, Lewis JT, Giakoumopoulos M, Allawi HT, Lidgard GP, Roberts LR, Ahlquist DA.

Hepatology. 2019 Mar;69(3):1180-1192. doi: 10.1002/hep.30244. Epub 2019 Feb 5.

6.

Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma.

Anderson BW, Suh YS, Choi B, Lee HJ, Yab TC, Taylor WR, Dukek BA, Berger CK, Cao X, Foote PH, Devens ME, Boardman LA, Kisiel JB, Mahoney DW, Slettedahl SW, Allawi HT, Lidgard GP, Smyrk TC, Yang HK, Ahlquist DA.

Clin Cancer Res. 2018 Nov 15;24(22):5724-5734. doi: 10.1158/1078-0432.CCR-17-3364. Epub 2018 May 29.

7.

Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease.

Kisiel JB, Klepp P, Allawi HT, Taylor WR, Giakoumopoulos M, Sander T, Yab TC, Moum BA, Lidgard GP, Brackmann S, Mahoney DW, Roseth A, Ahlquist DA.

Clin Gastroenterol Hepatol. 2019 Apr;17(5):914-921.e5. doi: 10.1016/j.cgh.2018.05.004. Epub 2018 May 15.

8.

Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue.

Levin TR, Corley DA, Jensen CD, Marks AR, Zhao WK, Zebrowski AM, Quinn VP, Browne LW, Taylor WR, Ahlquist DA, Lidgard GP, Berger BM.

Dig Dis Sci. 2017 Mar;62(3):678-688. doi: 10.1007/s10620-016-4433-6. Epub 2017 Jan 2.

9.

A Response to Keller's Commentary.

Berger BM, Lidgard GP.

Am J Med. 2016 Oct;129(10):e235. doi: 10.1016/j.amjmed.2016.06.001. Epub 2016 Jul 5. No abstract available.

PMID:
27393107
10.

Multitarget stool DNA testing for colorectal-cancer screening.

Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM.

N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.

11.

Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT).

Heigh RI, Yab TC, Taylor WR, Hussain FT, Smyrk TC, Mahoney DW, Domanico MJ, Berger BM, Lidgard GP, Ahlquist DA.

PLoS One. 2014 Jan 20;9(1):e85659. doi: 10.1371/journal.pone.0085659. eCollection 2014.

12.

Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia.

Lidgard GP, Domanico MJ, Bruinsma JJ, Light J, Gagrat ZD, Oldham-Haltom RL, Fourrier KD, Allawi H, Yab TC, Taylor WR, Simonson JA, Devens M, Heigh RI, Ahlquist DA, Berger BM.

Clin Gastroenterol Hepatol. 2013 Oct;11(10):1313-8. doi: 10.1016/j.cgh.2013.04.023. Epub 2013 Apr 29.

PMID:
23639600
13.

Quantification of methylated markers with a multiplex methylation-specific technology.

Zou H, Allawi H, Cao X, Domanico M, Harrington J, Taylor WR, Yab T, Ahlquist DA, Lidgard G.

Clin Chem. 2012 Feb;58(2):375-83. doi: 10.1373/clinchem.2011.171264. Epub 2011 Dec 22.

PMID:
22194633
14.

Next-generation stool DNA test accurately detects colorectal cancer and large adenomas.

Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, Butz ML, Thibodeau SN, Rabeneck L, Paszat LF, Kinzler KW, Vogelstein B, Bjerregaard NC, Laurberg S, Sørensen HT, Berger BM, Lidgard GP.

Gastroenterology. 2012 Feb;142(2):248-56; quiz e25-6. doi: 10.1053/j.gastro.2011.10.031. Epub 2011 Nov 4.

15.

The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia.

Ahlquist DA, Taylor WR, Mahoney DW, Zou H, Domanico M, Thibodeau SN, Boardman LA, Berger BM, Lidgard GP.

Clin Gastroenterol Hepatol. 2012 Mar;10(3):272-7.e1. doi: 10.1016/j.cgh.2011.10.008. Epub 2011 Oct 20.

16.

Faster, more sensitive flu tests to combat flu pandemic.

Lidgard G.

MLO Med Lab Obs. 2008 Oct;40(10):18, 20, 22-4. No abstract available.

PMID:
19054896
17.

Death-induced changes to the nuclear matrix: the use of anti-nuclear matrix antibodies to study agents of apoptosis.

Miller T, Beausang LA, Meneghini M, Lidgard G.

Biotechniques. 1993 Dec;15(6):1042-7.

PMID:
8292336
18.

Detection of nuclear matrix proteins in serum from cancer patients.

Miller TE, Beausang LA, Winchell LF, Lidgard GP.

Cancer Res. 1992 Jan 15;52(2):422-7.

19.
20.
21.

Radioimmunoassay for free thyroxine.

Fullarton J, Lidgard GP.

Lancet. 1979 Jul 7;2(8132):51. No abstract available.

PMID:
87938
22.

Bromocriptine suppression of the thyrotrophin response to thyrotrophin releasing hormone.

Yap PL, Davidson NM, Lidgard GP, Fyffe JA.

Clin Endocrinol (Oxf). 1978 Aug;9(2):179-83.

PMID:
100263
23.

Response to thyrotrophin releasing hormone in Klinefelter's syndrome.

Yap PL, Renton WB, Price WH, Fyffe JA, Lidgard GP.

Clin Endocrinol (Oxf). 1978 Mar;8(3):237-40.

PMID:
416925
24.

Lower oesophageal sphincter response to gastrin--pharmacological or physiological?

Henderson JM, Lidgard G, Osborne DH, Carter DC, Heading RC.

Gut. 1978 Feb;19(2):99-102.

25.

Effect of cimetidine on serum gastrin and gastric emptying in man.

Logan RF, Forrest JA, McLoughlin GP, Lidgard G, Heading RC.

Digestion. 1978;18(3-4):220-6.

PMID:
367853
26.

The effect of dialysate calcium concentration on 1alpha-hydroxyvitamin D3 on skeletal calcium loss and hyperparathyroidism in haemodialysis patients.

Winney RJ, Tothill P, Robson JS, Abbot SR, Lidgard GP, Cameron EH, Smith MA, Macpherson HN, Strong JA.

Clin Endocrinol (Oxf). 1977 Dec;7 Suppl:151s-158s.

PMID:
606413
27.
28.

Failure of luteinizing hormone-releasing hormone and insulin to further augment thyrotrophin release in primary hypothyroidism.

Harrower AD, Yap PL, Cameron EH, Lidgard GP.

Acta Endocrinol (Copenh). 1977 Nov;86(3):517-21.

PMID:
411302
29.

Prevalence of severe growth hormone deficiency.

Vimpani GV, Vimpani AF, Lidgard GP, Cameron EH, Farquhar JW.

Br Med J. 1977 Aug 13;2(6084):427-30.

30.

Spectrum of thyroid function in patient's remaining in remission after antithyroid drug therapy for thyrotoxicosis.

Irvine WJ, Gray RS, Toft AD, Seth J, Lidgard GP, Cameron EH.

Lancet. 1977 Jul 23;2(8030):179-81.

PMID:
69792
31.

Effect of cimetidine on the human lower oesophageal sphincter.

Osborne DH, Lennon J, Henderson M, Lidgard G, Creel R, Carter DC.

Gut. 1977 Feb;18(2):99-104.

32.

Propranolol in the treatment of thyrotoxicosis by subtotal thyroidectomy.

Toft AD, Irvine WJ, McIntosh D, MacLeod DA, Seth J, Cameron EH, Lidgard GP.

J Clin Endocrinol Metab. 1976 Dec;43(6):1312-6.

PMID:
826544
33.

Temporary hypothyroidism after surgical treatment of thyrotoxicosis.

Toft AD, Irvine WJ, McIntosh D, Seth J, Cameron EH, Lidgard GP.

Lancet. 1976 Oct 16;2(7990):817-8.

PMID:
61495
34.

Proceedings: The effect of cimetidine on lower oesophageal sphincter pressure in man.

Osborne DH, Lennon J, Henderson M, Lidgard G, Carter DC.

Gut. 1976 May;17(5):388-9. No abstract available.

PMID:
1278734
35.

Effect of histamine H2-receptor blockade on gastric emptying and serum gastrin in man.

Forrest JA, Heading RC, Park J, Carter DC, Lennon J, Lidgard G, Shearman DJ.

Scott Med J. 1976 Jan;21(1):23-7.

PMID:
769156
36.

Effect of the histamine H2-receptor antagonist, cimetidine, on gastric secretion and serum gastrin during insulin infusion in Man.

Carter DC, Forrest JA, Logan RA, Ansell I, Lidgard G, Heading RC, Shearman DJ.

Scand J Gastroenterol. 1976;11(6):565-70.

PMID:
10620
37.

Proceedings: Studies of the oesophageal antireflux mechanism using a modified rapid withdrawal manometric method and combined fluoroscopy.

Lennon J, Copeland W, Lidgard G, Eastwood M, Sircus W.

Gut. 1975 Oct;16(10):842. No abstract available.

PMID:
1205328
38.

Supplemental Content

Loading ...
Support Center